Joining us today is Panna Sharma, Chief Executive Officer, President and Director of Lantern Pharma, who will guide us through the demonstration and discuss the broader implications of this technology ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

SQL development is evolving fast, and Microsoft.Build.Sql is leading the charge. This next-generation SDK brings flexible project structures, better source control integration, automated build-time ...

As SQL development increasingly becomes part of full-stack workflows, developers are looking for ways to simplify their tooling without compromising capability. While SQL Server Management Studio ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Anthropic’s Claude agents outperformed human researchers and produced “alien science,” raising new questions about AI alignment and self-improvement.

CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.